Limits...
Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence.

Bishu K, Armstrong EJ - Vasc Health Risk Manag (2015)

Bottom Line: There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up.The Supera peripheral stent system has a braided nickel-titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery.This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, University of Colorado, Aurora, USA ; Denver VA Medical Center, Denver, CO, USA.

ABSTRACT
Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel-titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel-titanium alloy stent system with other stent platforms and angioplasty alone are needed.

No MeSH data available.


Related in: MedlinePlus

Severely calcified right SFA (A) with severe stenosis in the proximal and middle segment (B) treated with overlapping 5.5×150 mm and 5.5×60 mm Supera stents (C) with no significant residual stenosis (D).Abbreviation: SFA, superficial femoral artery.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508067&req=5

f3-vhrm-11-387: Severely calcified right SFA (A) with severe stenosis in the proximal and middle segment (B) treated with overlapping 5.5×150 mm and 5.5×60 mm Supera stents (C) with no significant residual stenosis (D).Abbreviation: SFA, superficial femoral artery.

Mentions: Figure 2 demonstrates an example of the use of the Supera stent for the treatment of a moderate-to-severely calcified SFA lesion with severe stenosis in a 62-year-old smoker who presented with severe lifestyle-limiting claudication. Figure 3 demonstrates the use of a Supera stent for the treatment of severe proximal and mid SFA calcification in an 82-year-old male with severe lifestyle-limiting claudication. In each case, the lesions were predilated with 6 mm balloons prior to stent deployment, in order to maximize stent expansion and limit elongation.


Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence.

Bishu K, Armstrong EJ - Vasc Health Risk Manag (2015)

Severely calcified right SFA (A) with severe stenosis in the proximal and middle segment (B) treated with overlapping 5.5×150 mm and 5.5×60 mm Supera stents (C) with no significant residual stenosis (D).Abbreviation: SFA, superficial femoral artery.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508067&req=5

f3-vhrm-11-387: Severely calcified right SFA (A) with severe stenosis in the proximal and middle segment (B) treated with overlapping 5.5×150 mm and 5.5×60 mm Supera stents (C) with no significant residual stenosis (D).Abbreviation: SFA, superficial femoral artery.
Mentions: Figure 2 demonstrates an example of the use of the Supera stent for the treatment of a moderate-to-severely calcified SFA lesion with severe stenosis in a 62-year-old smoker who presented with severe lifestyle-limiting claudication. Figure 3 demonstrates the use of a Supera stent for the treatment of severe proximal and mid SFA calcification in an 82-year-old male with severe lifestyle-limiting claudication. In each case, the lesions were predilated with 6 mm balloons prior to stent deployment, in order to maximize stent expansion and limit elongation.

Bottom Line: There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up.The Supera peripheral stent system has a braided nickel-titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery.This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, University of Colorado, Aurora, USA ; Denver VA Medical Center, Denver, CO, USA.

ABSTRACT
Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel-titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel-titanium alloy stent system with other stent platforms and angioplasty alone are needed.

No MeSH data available.


Related in: MedlinePlus